 |
|
|
| |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Non-Cirrhotic Asian Patients
With Genotype 1b Chronic Hepatitis C Virus Infection: ONYX-I Post-Treatment Week 24 Results
|
| |
| |
Reported by Jules levin
EASL 2017 April 19-23 Amsterdam Netherlands
Lai Wei1, Jinlin Hou2, Yan Luo3, Jeong Heo4, Chi-Jen Chu5, Zhongping Duan6, Mong Cho7, Jun Cheng8, Jun Li9, Jidong Jia10, Wenjing Lu3, Linda M Fredrick3, Tami Pilot-Mati as3,
Sarah Kopecky-Bromberg3, Niloufar Mobashery3, Wan-Long Chuang11
1Peking University People's Hospital, Beijing, China; 2Nanfang Hospital, Guangzhou, China; 3AbbVie Inc., North Chicago, Illinois, United States; 4Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Korea (the Republic of); 5Taipei Veterans General Hospital, Taipei City, Taiwan; 6Beijing YouAn Hospital, Capital Medical University, Beijing, China; 7Pusan National University Yangsan Hospital, Yangsan, Korea (the Republic of); 8Beijing Di Tan Hospital, Capital Medical University, Beijing, China; 9The First Affi liated Hospital with Nanjing Medical University, Nanjing, China; 10Beijing Friendship Hospital, Capital Medical University, Beijing, China;
11Kaohsiung Medical University, Kaohsiung City, Taiwan
|
| |
|
|
|
|
|
